As a novel identified RRM2 inhibitor, osalmid has been approved for treating cholecystitis, inflammation, and postcholecystectomy syndrome, which inhibited RRM2 activity by binding to hydrogen bond of RRM2 (Liu et al., 2016). The gene discussed is RRM2; the disease is postcholecystectomy syndrome.